EMA/175282/2021

European Medicines Agency decision

P/0147/2021

of 14 April 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ritlecitinib (EMEA-002451-PIP01-18) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0147/2021

of 14 April 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ritlecitinib (EMEA-002451-PIP01-18) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Pfizer Europe MA EEIG on 26 October 2018 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 February 2021, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for ritlecitinib, tablet, age appropriate oral formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for ritlecitinib, tablet, age appropriate oral formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for ritlecitinib, tablet, age appropriate oral formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 – Brussels, Belgium.

EMA/PDCO/12384/2021
Amsterdam, 26 February 2021

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-002451-PIP01-18

Scope of the application

Active substance(s):

Ritlecitinib

Condition(s):

Treatment of alopecia areata

Pharmaceutical form(s):

Tablet

Age appropriate oral formulation

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Pfizer Europe MA EEIG

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Pfizer Europe MA EEIG submitted for agreement to the European Medicines Agency on 26 October 2018 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 4 December 2018.

Supplementary information was provided by the applicant on 27 November 2020. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of alopecia areata

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- tablet, age appropriate oral formulation, oral use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of alopecia areata

2.1.1. Indication(s) targeted by the PIP

Treatment of severe alopecia areata (including alopecia universalis and alopecia totalis)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Tablet

Age appropriate oral formulation

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	**Study 1** Development of age appropriate oral formulation suitable for children less than 12 years of age
Non-clinical studies	1	**Study 2** Definitive juvenile toxicity study in rats with a 2-month recovery phase.

Area	Number of measures	Description
Clinical studies	3	**Study 3 (B7981031)** Open label, non-randomized, multiple once daily dose, PK/PD study in children 6 years to less than 12 years with severe alopecia areata **Study 4 (B7981027)** Randomized, double-blind, 24-week, placebo-controlled study to evaluate the safety and efficacy of ritlecitinib in children 6 years to less than 12 years of age with severe alopecia areata **Study 5 (B798128)** Long-term, extension study to evaluate the long-term safety and long-term efficacy of ritlecitinib in children 6 years to less than 12 years of age with severe alopecia areata (AA)
Extrapolation, modelling and simulation studies	4	**Study 6** Population PK analysis to characterize the PK of ritlecitinib in adult and adolescent AA participants and for dose-prediction in children 6 years to less than 12 years of age. **Study 7** Population PK analysis to characterize the PK of ritlecitinib in adult and paediatric AA subjects and evaluate overall dosing recommendation in the paediatric AA population. **Study 8** Longitudinal exposure-response analysis of absolute SALT (severity of alopecia tool) score to characterize the temporal relationship of exposure-response of ritlecitinib on scalp hair growth in AA subjects. **Study 9** Extrapolation study to support the extrapolation of efficacy, safety and clinical PK data of ritlecitinib to adolescents with severe AA.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By November 2029
Deferral for one or more measures contained in the paediatric investigation plan:	Yes